A historic innovation
Since 1983, Roche has pioneered the advancement of PCR analysis, which is recognized as a gold standard in laboratory diagnostics. The cobas® Liat® PCR System replicates extracted DNA or RNA from patient samples to accurately identify infectious diseases. Using Roche PCR technology, laboratory-quality sensitivity and specificity are achieved across assays, significantly reducing the risk of false negative and false positive results.1
cobas® Strep A1
cobas® Influenza A/B2
cobas® Influenza A/B & RSV3
Quality without compromise
Patients deserve the best care possible—that means reliable results in a reasonably short amount of time. Current diagnostic options offer a trade-off between speed or accuracy, and since many diseases present similar symptoms at early stages, the need for a reliably accurate point-of-care testing solution is high.
Explore the pros and cons of current diagnostic options
Signs & symptoms
Quick diagnosis, based on knowledge and experience
Could lead to incorrect antibiotic treatment
On-site rapid antigen test
Fast results, easy to use
Potentially less accurate, with uncertainty around negative results
Highly accurate and definitive
Prolongs time for patient diagnosis
Explore the cobas® Liat® System
*Compared to culture and latex agglutination for Strep A typing; CLIA data.
**Compared to viral culture.
†Compared to an FDA-cleared laboratory based multiplexed real-time reverse transcription PCR (RT-PCR) test; CLIA data.
††Compared to direct culture.
‡Compared to direct and enriched culture.
cobas® Strep A, cobas® Influenza A/B and cobas® Influenza A/B & RSV are CE-IVD and FDA 510(k) cleared; CLIA waived. cobas® Cdiff is CE-IVD cleared.
References: 1. cobas® Strep A [package insert]. Pleasanton, CA: Roche Molecular Systems, Inc., 2016. 2. cobas® Influenza A/B [package insert]. Pleasanton, CA: Roche Molecular Systems, Inc., 2015. 3. cobas® Influenza A/B & RSV [package insert]. Pleasanton, CA: Roche Molecular Systems, Inc., 2016. 4. cobas® Cdiff [package insert].